Clearmind Medicine Inc (CMND)
1.11
+0.03
(+2.78%)
USD |
NASDAQ |
Jun 14, 16:00
1.11
0.00 (0.00%)
After-Hours: 17:25
Clearmind Medicine Enterprise Value: -5.850M for June 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 13, 2024 | -5.850M |
| June 12, 2024 | -5.818M |
| June 11, 2024 | -6.046M |
| June 10, 2024 | -6.046M |
| June 07, 2024 | -6.005M |
| June 06, 2024 | -5.975M |
| June 05, 2024 | -5.883M |
| June 04, 2024 | -5.883M |
| June 03, 2024 | -5.818M |
| May 31, 2024 | -5.687M |
| May 30, 2024 | -5.654M |
| May 29, 2024 | -5.687M |
| May 28, 2024 | -5.654M |
| May 24, 2024 | -5.622M |
| May 23, 2024 | -5.704M |
| May 22, 2024 | -5.589M |
| May 21, 2024 | -5.459M |
| May 20, 2024 | -5.459M |
| May 17, 2024 | -5.394M |
| May 16, 2024 | -5.165M |
| May 15, 2024 | -5.198M |
| May 14, 2024 | -5.165M |
| May 13, 2024 | -5.165M |
| May 10, 2024 | -4.806M |
| May 09, 2024 | -4.480M |
| Date | Value |
|---|---|
| May 08, 2024 | -4.578M |
| May 07, 2024 | -4.546M |
| May 06, 2024 | -5.557M |
| May 03, 2024 | -5.492M |
| May 02, 2024 | -5.556M |
| May 01, 2024 | -5.524M |
| April 30, 2024 | -5.499M |
| April 29, 2024 | -5.459M |
| April 26, 2024 | -5.589M |
| April 25, 2024 | -5.459M |
| April 24, 2024 | -5.426M |
| April 23, 2024 | -5.426M |
| April 22, 2024 | -5.492M |
| April 19, 2024 | -5.508M |
| April 18, 2024 | -5.530M |
| April 17, 2024 | -5.492M |
| April 16, 2024 | -5.394M |
| April 15, 2024 | -5.280M |
| April 12, 2024 | -5.328M |
| April 11, 2024 | -5.198M |
| April 10, 2024 | -5.230M |
| April 09, 2024 | -5.068M |
| April 08, 2024 | -5.720M |
| April 05, 2024 | -5.622M |
| April 04, 2024 | -5.622M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-6.046M
Minimum
Jun 10 2024
22.37M
Maximum
Nov 15 2021
5.857M
Average
6.212M
Median
Enterprise Value Benchmarks
| Acasti Pharma Inc | 5.289M |
| Aurinia Pharmaceuticals Inc | 414.66M |
| Edesa Biotech Inc | 11.25M |
| Lexaria Bioscience Corp | 37.23M |
| InMed Pharmaceuticals Inc | -5.616M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.368M |
| Total Expenses (Quarterly) | 1.384M |
| EPS Diluted (Quarterly) | -0.90 |
| Earnings Yield | -1.75K% |